Boston, MA 06\/12\/2014 (wallstreetpr) \u2013 Medical technology company, Becton, Dickinson and Co. (NYSE:BDX)<\/b> shares were sold by an insider taking advantage of the prevailing price, which is close to a year high price. The action of an insider comes on the backdrop of a consensus among analysts for a Hold rating of its shares.<\/p>\n
Insider Sells Shares<\/b><\/p>\n
The company\u2019s executive vice president Gary Cohen had offloaded about 12.4K shares on June 10, according to the company\u2019s filing with Securities Exchange Commission or SEC. The stock hit a high of $120.08 and a low of $118.75 on June 10 before it closed at $119.45. However, the executive could sell part of his stake at an average price of $119.24. It has yielded him a total of approximately $1.48 million.<\/p>\n
Even after selling sizeable shares, the Becton, Dickinson and Co. executive is still holding little over 70K shares of the company. At current market price, his holding is valued around $8.39 million.<\/p>\n
The stock has a yearly high of $120.66 and a low of $94.25. On June 11, the stock closed below at $119.06. The technical barometer of 50-day and 200-day moving averages was $116.06 and $112.94 respectively, indicating higher trading price currently. The sale of shares by an insider has not impacted the overall performance of the stock on Wednesday.<\/p>\n
Interestingly, Becton, Dickinson and Co. (NYSE:BDX) \u2019s first quarter earnings fell shy of analysts\u2019 expectations by five cents a year and revenue by $0.02 billion.<\/p>\n
Analyst Rating<\/b><\/p>\n
The consensus rating among analysts is a Hold rating on Becton, Dickinson and Co. shares with a price tag of $109.62. Some of the analysts like Sun Trust have lifted the price target to $138.00 from $128.00 with a Buy rating of the company\u2019s stock. RBC Capital Markets has a Sector Perform rating.<\/p>\n
While only one analyst put the stock on Sell radar, five analysts have a hold rating and six others have a Buy rating of Becton, Dickinson and Co. shares.<\/p>\n
Becton, Dickinson and Co. (NYSE:BDX) \u00a0is scheduled to announce its second quarter results on July 28 and analysts\u2019 expect Becton, Dickinson and Co. to earn $1.67 a share on revenues of $2.14 billion.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 06\/12\/2014 (wallstreetpr) \u2013 Medical technology company, Becton, Dickinson and Co. (NYSE:BDX) shares were sold by an insider taking advantage of the prevailing price, […]<\/p>\n","protected":false},"author":32,"featured_media":25574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[7265,1774],"stock_ticker":[],"class_list":["post-25572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-becton-dickinson-and-co-nysebdx","tag-nysebdx","entry"],"acf":[],"yoast_head":"\n